NCT04297436View on ClinicalTrials.gov

Gonococcal Vaccine Study in Key Populations in Kenya

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2021

Primary Completion Date

February 5, 2022

Study Completion Date

February 28, 2022

Conditions
Gonorrhea
Interventions
BIOLOGICAL

4CMenB (Bexsero®) vaccine

Tthe 4CMenB vaccine (Bexsero®) contains the MeNZB OMV component plus three recombinant antigens (NadA, fHBP-GNA2091, and NHBA-GNA1030. The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.

Trial Locations (1)

Unknown

KEMRI-Wellcome Trust Research Programme, Kilifi

All Listed Sponsors
collaborator

KEMRI-Wellcome Trust Collaborative Research Program

OTHER

lead

University of Oxford

OTHER